Items Tagged ‘Bladder Cancer’

June 8th, 2016

Tecentriq® Approved for Bladder Cancer

By

The United States Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) for the treatment of bladder cancer. Atezolizumab is an immunotherapy agent referred to as a PD-1/PD-L1 inhibitor, and is the first agent in this class to be approved for the treatment of bladder cancer. Urothelial carcinoma (formerly known as transitional cell carcinoma) is […]

View full entry

Tags: atezolizumab, Bladder Cancer, inhibitor, News, PD-1, PD-L1, Stage IV/Metastatic Bladder Cancer, Tecentriq, urothelial carcinoma


June 8th, 2016

Tecentriq® Effective as Initial Therapy in Advanced Bladder Cancer

By

The immunotherapy agent Tecentriq® (atezolizumab) provides anti-cancer activity when used as initial therapy among patients with advanced bladder cancer who are not able to tolerate standard therapy. These results were recently presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). Bladder cancer will be diagnosed in approximately 77,000 people in […]

View full entry

Tags: advanced, atezolizumab, Bladder Cancer, elderly, immunotherapy Tecentriq, News, smokers, Stage IV/Metastatic Bladder Cancer, urothlial carcinoma


March 14th, 2016

Radiotherapy for Prostate Cancer Increases Risk of Secondary Cancers

By

Patients with prostate cancer considering radiation therapy should now be informed that radiotherapy raises the risk of developing a secondary cancer. Prostate cancer patients who undergo radiotherapy raise their risk of getting other cancers by nearly 70 percent, according to the results of a new study. There is a well-documented association between exposure to radiation […]

View full entry

Tags: Bladder Cancer, bowel cancer, carcinogenesis, Colon Cancer, exposure, Hodgkin's Lymphoma, News, Prostate Cancer, radiation therapy, Rectal Cancer, secondary cancer


January 21st, 2016

Atezolizumab Provides Long-Lasting Anti-Cancer Responses in Advanced Bladder Cancer

By

The immunotherapeutic agent, atezolizumab, which is still in investigative stages, provides high rates of anti-cancer responses among patients with advanced bladder cancer. These results were recently presented at the 2016 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO GU). Urothelial carcinoma (formerly known as transitional cell carcinoma) is a cancer involving parts […]

View full entry

Tags: atezolizumab, Bladder Cancer, News, urothelial carcinoma


March 31st, 2015

Chemotherapy after Surgery Appears to Improve Survival in Advanced Bladder Cancer

By

Patients with advanced bladder cancer who receive chemotherapy after surgery to remove the bladder have better overall survival than patients who undergo surgery alone. These findings were presented at the 2015 Genitourinary Cancers Symposium on February 26–28 in Orlando, Florida. Patients with Stage III, or advanced, bladder cancer have cancer that invades through the connective […]

View full entry

Tags: adjuvant chemotherapy, advanced, Bladder Cancer, genitourinary cancer, News, stage III, Stage III Bladder Cancer


March 30th, 2015

Votrient® plus Taxol® Promising in Relapsed and Refractory Bladder Cancer

By

The treatment combination of Votrient® (pazopanib) plus Taxol® (paclitaxel) appears active against bladder cancer that has not responded to or come back after previous therapy. These findings were presented at the 2015 Genitourinary Cancers Symposium on February 26–28 in Orlando, Florida. Bladder cancer is diagnosed in roughly 50,000 men and 17,000 women annually in the […]

View full entry

Tags: Bladder Cancer, News, paclitaxel, pazopanib, Phase II study, Recurrent Bladder Cancer, Stages II-III Bladder Cancer, Taxol, Votrient


March 16th, 2015

Cyramza® plus Taxotere® Promising in Advanced Bladder Cancer

By

The treatment combination of Cyramza® (ramucirumab) plus Taxotere® (docetaxel) appears to extend progression-free survival in patients with advanced bladder cancer that has relapse after previous treatment. These findings were presented at the 2015 Genitourinary Cancers Symposium on February 26–28 in Orlando, Florida. Bladder cancer is diagnosed in roughly 50,000 men and 17,000 women annually in […]

View full entry

Tags: Bladder Cancer, cyramza, News, Recurrent Bladder Cancer, Stage IV/Metastatic Bladder Cancer, taxotere


July 29th, 2014

Studies Evaluate Robot Assisted Cystectomy Treatment of Bladder Cancer

By

The bladder is a hollow organ located in the pelvis. Its primary function is to store urine. The bladder has a muscular wall that allows it to get larger and smaller as urine is stored or emptied. Bladder cancer is diagnosed in roughly 50,000 men and 17,000 women annually in the United States.  Patients with […]

View full entry

Tags: Bladder Cancer, cystecomy, News, rarc, robotic-assisted radical cystectomy, Stages 0-I Bladder Cancer, Stages II-III Bladder Cancer


June 23rd, 2014

Survival Benefit with Immediate Adjuvant Chemotherapy in Invasive Bladder Cancer

By

Results from a recent Phase III clinical trial suggest that patients with invasive bladder cancer may benefit from treatment with immediate adjuvant chemotherapy. These finding were presented at the 2014 American Society of Clinical Oncology (ASCO) meeting held in Chicago, May 31–June 3. Patients with Stage III, or invasive, bladder cancer have cancer that invades […]

View full entry

Tags: Bladder Cancer, News, Recurrent Bladder Cancer, Stage III Bladder Cancer, Stage IV/Metastatic Bladder Cancer, Stages II-III Bladder Cancer, surgery


June 17th, 2014

Immediate Cisplatin-Based Chemotherapy Extends Progression-Free Survival in Invasive Bladder Cancer

By

A report at the 2014 American Society of Clinical Oncologists meeting indicates that immediate use of cisplatin-based chemotherapy offers significant improvement in progression-free survival over deferred treatment in invasive bladder cancer patients. The study concerned only patients who have had prior surgical resection. There was no significant improvement measured in overall survival. The EORTC clinical […]

View full entry

Tags: asco, Bladder Cancer, cisplatin, invasive bladder cancer, News, Stage III Bladder Cancer, Stages II-III Bladder Cancer


June 12th, 2014

Experimental Drug Shows Promise for Treatment of Metastatic Bladder Cancer

By

According to results of a Phase I trial presented at the 2014 annual meeting of the American Society of Clinical Oncology, an investigative drug, MPDL3280A, demonstrates promise for the treatment of PD-L1 positive metastatic bladder cancer. Bladder cancer is diagnosed in roughly 50,000 men and 17,000 women annually in the United States. Bladder cancer is the […]

View full entry

Tags: Bladder Cancer, MPDL3280A, News, PD-L1, Recurrent Bladder Cancer, Stage IV/Metastatic Bladder Cancer


January 20th, 2014

Radiation for Uterine Cancer May Increase Risk of Bladder Cancer

By

Radiation therapy used to treat uterine cancer may increase the risk of bladder cancer later in life, according to the results of a study published in BJU International. Uterine (endometrial) cancer is one of the most common gynecologic cancers in women, with more than 49,000 new cases and more than 7,700 deaths from the disease each […]

View full entry

Tags: Bladder Cancer, News, Recurrent Uterine Cancer, Screening/Prevention Bladder Cancer, Screening/Prevention Uterine Cancer, Stage IV Uterine Cancer, Stages I-III Uterine Cancer, Uterine Cancer


September 16th, 2013

End-of-Life Care Remains Aggressive, Despite Patient Wishes

By

Although most patients with advanced cancer prefer hospice or palliative care that minimizes symptoms, many continue to receive aggressive treatment during their final weeks and months of life. In fact, elderly patients with advanced cancer often receive intensive treatment until the last month of life and hospice care is often delayed until the final three […]

View full entry

Tags: All Cancer Types, Anal Cancer, Bladder Cancer, Bone Cancer, Brain Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, HIV Related Cancers


May 15th, 2013

Following Lifestyle Recommendations Reduces Risk of Cancer Death

By

People who follow the diet and lifestyle recommendations laid out by the World Cancer Research Fund (WCRF) and the American Institute for Cancer Research (AICR) have a 34 percent reduced risk of dying from several diseases and specifically, a 20 percent reduced risk of dying from cancer compared to people who don’t follow the recommendations, […]

View full entry

Tags: Anal Cancer, Bladder Cancer, Bone Cancer, Brain Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Esophageal Cancer, Gastric Cancer, General, Head and Neck Cancer, HIV Related Cancers


February 11th, 2013

Cancer Deaths on the Decline

By

Overall cancer death rates continue to decline in both men and women and across major ethnic and racial groups, according to the annual Status of Cancer report published in the Journal of the National Cancer Institute. What’s more—cancer incidence rates for both sexes combined decreased by 1.5 percent per year from 2000 to 2009 and […]

View full entry

Tags: Anal Cancer, Bladder Cancer, Bone Cancer, Brain Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Esophageal Cancer, Gastric Cancer, General, Head and Neck Cancer, HIV Related Cancers